Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Esclusivo latte materno nei NEOnati prematuri e fattori di rischio di invecchiamento vascolare precoce (NEOVASC) (NEOVASC)

15 settembre 2026 aggiornato da: Ursula Kohlendorfer, Prolacta Bioscience

Effetti di una dieta esclusiva a base di latte materno nei neonati prematuri sui fattori di rischio di invecchiamento vascolare precoce (NEOVASC)

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.

The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.

The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.

Tipo di studio

Interventistico

Iscrizione (Stimato)

200

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Tyrol
      • Innsbruck, Tyrol, Austria, A-6020
        • Reclutamento
        • Medical University of Innsbruck
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Christoph Binder, MD
        • Investigatore principale:
          • Martin Wald, MD
        • Investigatore principale:
          • Burkhard Simma, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 giorno a 5 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Preterm-born group:

Inclusion Criteria:

  1. Extremely preterm infants with a birth weight of 500-1250g.
  2. Feeding is NPO or exclusive human milk prior to enrollment.
  3. Parent(s) willing to sign informed consent.-

Exclusion Criteria:

  1. Infants with a birth weight <500g or >1250g
  2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
  3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
  4. Presence of major congenital malformation.
  5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
  6. Parent(s) not willing to sign informed consent.
  7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).

Term-born group:

Inclusion criteria

  1. Term-born children with an adequate birth weight
  2. Parent(s) willing to sign informed consent

Exclusion criteria

  1. Subjects with acute or chronic illness
  2. Parent(s) not willing to sign informed consent

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Randomized study product group

receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Comparatore attivo: Randomized control group

receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Nessun intervento: Term control group

Term-born controls as a reference group for outcome parameters

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting blood glucose
Lasso di tempo: "First day of life" up to "five years of life"

Primary outcome is the difference in fasting blood glucose at five years of age

"First day of life" up to "five years of life"
Blood pressure
Lasso di tempo: "First day of life" up to "five years"

Primary outcome is the difference in blood pressure at five years of age

"First day of life" up to "five years"
Distensibility of aorta
Lasso di tempo: "First day of life" up to "five years"

Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age

"First day of life" up to "five years"

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting blood glucose
Lasso di tempo: "First day of life" up to "24 months"

Secondary outcome is fasting glucose at a corrected age of one and two years.

"First day of life" up to "24 months"
Blood pressure
Lasso di tempo: "First day of life" up to "24 months"

Secondary outcome is blood pressure at a corrected age of one and two years.

"First day of life" up to "24 months"
BMI
Lasso di tempo: "First day of life" up to "five years"

Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"First day of life" up to "five years"
Insulin sensitivity
Lasso di tempo: "First day of life" up to "five years"

Secondary outcome is insulin sensitivity at five years of age

"First day of life" up to "five years"
Lipid profile
Lasso di tempo: "First day of life" up to "five years"

Secondary outcome is lipid profile at five years of age

"First day of life" up to "five years"

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting blood glucose
Lasso di tempo: "five years of age"

Difference in fasting blood glucose between preterm- and term-born children at five years of age

"five years of age"
Blood pressure
Lasso di tempo: "five years of age"

Difference in blood pressure between preterm- and term-born children at five years of age

"five years of age"
Distensibility of the descending aorta
Lasso di tempo: "five years of age"

Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children

"five years of age"
BMI
Lasso di tempo: "five years of age"

Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"five years of age"
Insulin sensitivity
Lasso di tempo: "five years of age"

Difference in insulin sensitivity between preterm- and term-born children at five years of age

"five years of age"
Lipid profile
Lasso di tempo: "five years of age"

Difference in lipid profile between preterm- and term-born children at five years of age

"five years of age"

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 ottobre 2020

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

26 maggio 2020

Primo inviato che soddisfa i criteri di controllo qualità

30 maggio 2020

Primo Inserito (Effettivo)

4 giugno 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NEOVASC
  • 868624 (Altro numero di sovvenzione/finanziamento: Austrian Research Promotion Agency)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi